Patients With Schizophrenia clinical trials

Explore recruiting patients with schizophrenia clinical trials.

Recruiting patients with schizophrenia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Patients With Schizophrenia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Patients with Schizophrenia, Followed by an Open-label Extension Phase

Romania

Phase II and Phase III (Integrated) EU CTIS Study details

EVALUATION OF THE EFFICACY OF TOLCAPONE AS A GENOTYPE-BASED TARGETED COGNITIVE ENHANCER IN SCHIZOPHRENIA, BASED ON THE POLYMORPHISM RS4680

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia

Romania, Bulgaria, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Assessment of microglial activation in patients with schizophrenia stratified for C4 complement by PET using [18F]DPA-714

France

Phase II and Phase III (Integrated) EU CTIS Study details

Ketamine for the treatment of depressive and negative symptoms in patients with schizophrenia: a randomized controlled cross-over pilot study.

Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Patients With Schizophrenia trials by city

Patients With Schizophrenia in Toronto Patients With Schizophrenia in Vancouver Patients With Schizophrenia in Montreal Patients With Schizophrenia in Calgary Patients With Schizophrenia in Edmonton Patients With Schizophrenia in Ottawa Patients With Schizophrenia in Winnipeg Patients With Schizophrenia in Quebec City Patients With Schizophrenia in Hamilton Patients With Schizophrenia in Kitchener Patients With Schizophrenia in London Patients With Schizophrenia in Halifax Patients With Schizophrenia in New York Patients With Schizophrenia in Los Angeles Patients With Schizophrenia in Chicago Patients With Schizophrenia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease